PHASE-I TRIAL OF RECOMBINANT INTERFERON-GAMMA IN CANCER-PATIENTS

[1] ALKATIB A, 1984, P AM ASSOC CANC RES, V25, P235

[2] ALKATIB A, 1985, P AM ASSOC CANC RES, V26, P275

[3] BASHAM TY, 1983, J IMMUNOL, V130, P1492

[4] PURIFIED HUMAN IMMUNE INTERFERON HAS MORE POTENT ANTICELLULAR ACTIVITY THAN FIBROBLAST OR LEUKOCYTE INTERFERON [J]. CELLULAR IMMUNOLOGY, 1980, 49 (02) : 390 - 394

[5] BOCCI V, 1982, J GEN VIROL, V60, P297

[6] BORDEN EC, 1981, PROG HEMATOL, V12, P299

[7] EVIDENCE THAT TYPE-I AND TYPE-II INTERFERONS HAVE DIFFERENT RECEPTORS [J]. NATURE, 1981, 294 (5843) : 768 - 770

[8] CRANE JL, 1978, J NATL CANCER I, V61, P871

[9] SYNERGISTIC ANTIVIRAL AND ANTIPROLIFERATIVE ACTIVITIES OF ESCHERICHIA-COLI-DERIVED HUMAN ALPHA-INTERFERON, BETA-INTERFERON, AND GAMMA-INTERFERON [J]. JOURNAL OF VIROLOGY, 1984, 49 (02) : 490 - 496

[10] DIANZANI F, 1978, P SOC EXP BIOL MED, V159, P94

[1] ALKATIB A, 1984, P AM ASSOC CANC RES, V25, P235

[2] ALKATIB A, 1985, P AM ASSOC CANC RES, V26, P275

[3] BASHAM TY, 1983, J IMMUNOL, V130, P1492

[4] PURIFIED HUMAN IMMUNE INTERFERON HAS MORE POTENT ANTICELLULAR ACTIVITY THAN FIBROBLAST OR LEUKOCYTE INTERFERON [J]. CELLULAR IMMUNOLOGY, 1980, 49 (02) : 390 - 394

[5] BOCCI V, 1982, J GEN VIROL, V60, P297

[6] BORDEN EC, 1981, PROG HEMATOL, V12, P299

[7] EVIDENCE THAT TYPE-I AND TYPE-II INTERFERONS HAVE DIFFERENT RECEPTORS [J]. NATURE, 1981, 294 (5843) : 768 - 770

[8] CRANE JL, 1978, J NATL CANCER I, V61, P871

[9] SYNERGISTIC ANTIVIRAL AND ANTIPROLIFERATIVE ACTIVITIES OF ESCHERICHIA-COLI-DERIVED HUMAN ALPHA-INTERFERON, BETA-INTERFERON, AND GAMMA-INTERFERON [J]. JOURNAL OF VIROLOGY, 1984, 49 (02) : 490 - 496

[10] DIANZANI F, 1978, P SOC EXP BIOL MED, V159, P94